SynthesisFrontiers in medicine2026
The proteomic architecture of clonal hematopoiesis: a systematic review of niche remodeling and multi-compartment predictors of malignant transformation.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clonal hematopoiesis of indeterminate potential (CHIP) is a precursor to myeloid malignancies, yet the functional proteomic landscape that governs clonal fitness and microenvironmental remodeling remains poorly understood. This systematic review consolidates high-resolution proteomic evidence to map the transition from stable CHIP to overt malignancy. Methods: Following PRISMA 2020 guidelines, we analyzed 15 high-quality studies (selected from 83 initial records) published between 2015 and 2025. The review integrates data from diverse proteomic platforms-including DIA-MS, TMT labeling, and Olink high-plex panels across hematopoietic stem/progenitor cells (HSPCs), the bone marrow niche, and blood. Risk of bias was rigorously assessed using ROBINS-E, QUIPS, and SYRCLE frameworks. Results: Synthesis of the evidence reveals a profound "Genotype-Proteotype Gap," characterized by a low median mRNA-protein correlation (0.30) in aging stem cells. Clonal expansion is associated with a non-linear "functional niche failure" exceeding a 5% VAF threshold, marked by the emergence of inflammatory mesenchymal stromal cells (iMSCs) expressing IL-1R1 and CD44. Systemically, proteomic risk scores utilizing markers such as F7, BIN2, and CXCL11 can predict incident myeloid neoplasms over a decade before clinical diagnosis. Evidence strength varies substantially, with high-strength support for plasma predictive signatures and preliminary-to-moderate support for mechanistic findings from smaller cohorts. Conclusion: This systematic review identifies that malignant progression is dictated by a qualitative proteomic "switch" and structural niche reorganization. However, causal relationships remain to be definitively established. We identify a critical "Spatial Architecture Gap" in current research, highlighting the need for spatial proteomic platforms to map the physical "handshake" between mutant clones and their inflammatory environment to enable early clinical interception.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.